Symposium:
109. State-of-the-Art in HIV
Saturday, October 22, 2011: 8:15 AM-9:45 AM
Room: 210ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss PrEP in the United States
  • recognize and explain new regimens and strategies in HIV Treatment 
  • describe the best options for initializing and managing ART therapy

Target Audience: HIV-Treating Clinicians and Clinicians Caring for at-risk Patients, Pharmacists, Lab Personnel, Infectious Diseases Physicians, HIV Clinicians, Clinicians, Academicians

Tracks: HIV

Moderators:  Joel Gallant, MD, MPH, FIDSA, John Hopkins University School of Medicine and Michael Horberg, MD MAS, Kaiser Permanente Medical Care Program

Presentations:

8:15 AM
824
PrEP in the US
Dawn K Smith, MD, MS, MPH

9:15 AM
826

CME Credits: Maximum of 1.5 hours of Category 1 credit possible

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-139-L02-P

Disclosures:

J. Gallant, Bristol-Myers Squibb: Scientific Advisor, Consulting fee
Gilead Sciences: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient
Merck & Co.: Scientific Advisor, Consulting fee
Janssen Therapeutics: Scientific Advisor, Consulting fee
Sangamo Biosciences: Scientific Advisor, Consulting fee
RAPID Pharmaceuticals: Consultant, Consulting fee

M. Horberg, Pfizer: Grant Investigator, Research grant
Merck & Co.: Grant Investigator, Research grant

D. K. Smith, None

M. Horberg, Pfizer: Grant Investigator, Research grant
Merck & Co.: Grant Investigator, Research grant

P. Sax, Abbott: Consultant, Consulting fee
BMS: Investigator and Scientific Advisor, Consulting fee and Research grant
Gilead: Investigator and Scientific Advisor, Consulting fee and Research grant
Merck: Investigator and Scientific Advisor, Consulting fee and Research grant
GSK: Consultant and Investigator, Consulting fee and Research grant
Tibotec: Investigator and Scientific Advisor, Consulting fee and Grant recipient

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.